BioCentury
ARTICLE | Clinical News

Innate reports additional Phase I data for IPH4102 in cutaneous T cell lymphoma (CTCL)

November 30, 2017 11:37 PM UTC

In October, Innate Pharma S.A. (Euronext:IPH) reported additional data from the dose escalation portion of the Phase I IPH4102-101 trial. Among 20 patients with relapsed or refractory Sezary syndrome who were killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 (KIR3DL2; CD158K)-positive, IV IPH4102 led to an objective response rate (ORR) of 50%, an ORR lasting at least four months (ORR4) of 40%, a disease control rate of 90%, a median duration of response of 9.9 months and a median progression-free survival (PFS) of 10.8 months. The recommended Phase 2 dose was identified at 750 mg, a fixed-dose equivalent to 10 mg/kg.

The open-label, international trial enrolled 25 patients with KIR3DL2-positive, relapsed or refractory cutaneous T cell lymphoma (CTCL). Among all 25 patients, the ORR was 44%, the ORR4 was 36%, the median duration of response was 8.2 months and the PFS was 9.8 months. Data were reported at the EORTC CLTF meeting in London...